ONWARD Medical Announces Major Capital Increase
ONWARD Medical N.V., a front runner in medical technology dedicated to spinal cord injury therapies, is making headlines with the announcement of a significant capital increase valued at approximately EUR 40 million. This capital raise includes a cornerstone investment of EUR 22.5 million from Ottobock SE & Co. KGaA, known for their pioneering work in prosthetics and mobility solutions. This partnership underlines a mutual commitment to enhancing solutions for individuals with spinal cord injuries (SCI) and movement-related disabilities.
Strategic Collaboration with Ottobock
The investment from Ottobock is not just financial; it marks the beginning of a strategic alliance aimed at innovating treatment landscapes for those impacted by functional challenges following spinal cord injury. According to Dave Marver, CEO of ONWARD Medical, this collaboration will harness Ottobock's extensive expertise in mobility solutions to explore synergistic opportunities. This partnership aims to leverage ONWARD's advanced therapies for broader patient benefits.
Enhancing Therapy Options
Both corporations envision a future where their combined technologies can redefine the therapeutic approach for SCI patients. As Professor Hans Georg Näder from Ottobock stated, ONWARD possesses groundbreaking potential to revolutionize spinal injury treatment. Fusing ONWARD's innovative techniques with Ottobock’s established operations opens pathways for more effective, tailored solutions designed to restore mobility and independence for individuals.
Funding and Allocation of Proceeds
ONWARD Medical plans to allocate the funds raised through this capital increase toward several key areas. Up to 40% of the net proceeds will enhance research and development activities, significantly including clinical studies related to their investigational therapies like the ARC-EX and ARC-IM Systems. Aimed at restoring hand and arm function, these devices embody the company's commitment to pushing boundaries in medical technology.
Commercial Launch Preparations
Furthermore, 30% of the capital will directly support the upcoming commercial launch of the ARC-EX System in the United States, which involves hiring a dedicated sales team, creating educational materials, and engaging in customer training. These steps are critical as ONWARD prepares to elevate patient care through improved product access.
Private Placement Details
As part of this initiative, the New Shares are being offered to qualified investors in a private placement. Only a limited duration will allow for broader engagement from investors aiming for participation. This exclusive offer ensures the management of trading procedures while creating an environment conducive to substantial investor involvement.
Future Prospects and Financial Guidance
The outlook remains optimistic, with ONWARD expecting the Private Placement to secure a cash runway for at least two years. This projected financial stability is crucial as they continue to navigate through regulatory processes and product advancements. Their investments in the ARC therapy systems and related technologies are poised to transform therapeutic practices for SCI.
Capital Increase and Market Impact
The strategic nature of this announcement surfaces a pivotal moment for both ONWARD Medical and the sector at large. As they proceed with the bookbuilding period, anticipation is building among stakeholders and investors alike. The timing for the listing is scheduled, with shares likely making their debut on notable European exchanges, including Euronext Brussels and Euronext Amsterdam.
Frequently Asked Questions
What is the purpose of ONWARD Medical's recent capital increase?
The capital increase aims to fund various activities, including research and development, to advance spinal cord injury therapies and facilitate the commercial launch of innovative products.
Who is Ottobock and what role do they play in this collaboration?
Ottobock is a leading company in mobility solutions, including prosthetics. They are contributing EUR 22.5 million as a cornerstone investor and partner, bringing their expertise to enhance ONWARD's offerings.
What are the key technologies ONWARD is developing?
ONWARD is focusing on several investigational systems such as the ARC-EX and ARC-IM, designed to restore functional movement in people with SCI and improve health outcomes.
How will the funds be allocated?
The funds will support research and development, commercial launches, and operational enhancements, ensuring ONWARD can innovate and effectively serve its market.
When can investors expect the New Shares to be available?
The New Shares are anticipated to be listed and available for trading shortly following the bookbuilding process, with expectations set around a specific timeline that includes the completion of trading suspension regulations.
